(triphenyl-λ5-phosphanyl)methanol

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (triphenyl-λ5-phosphanyl)methanol
• 化学式: C₁₉H₁₉OP
• 分子量: 294.3
• InChiKey: DLMBZVMRNLOJFP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• GEL POLYMER ELECTROLYTE COMPOSITION
  申请人：Kuraray Co., Ltd.

  公开号：EP2524932A1

  公开（公告）日：2012-11-21

  An objective of the present invention is to provide a gel polymer electrolyte composition which exhibits excellent electrolyte retaining ability, excellent ion conductivity, higher mechanical strength and excellent shape preservation, which does not require an extra step for crosslinking, and which can provide a secondary battery with excellent cycle properties and a vinyl acetal polymer used for a gel polymer electrolyte composition. There are provided a vinyl acetal polymer for a gel polymer electrolyte composition, wherein the vinyl acetal polymer has a cationic functional group, as well as a gel polymer electrolyte composition comprising the vinyl acetal polymer and an electrolyte solution, wherein a weight ratio of the vinyl acetal polymer to the electrolyte solution is 0.5:99.5 to 9:91.

  本发明的目的是提供一种凝胶聚合物电解质组合物，该组合物具有优异的电解质保持能力、优异的离子传导性、较高的机械强度和优异的形状保持性，不需要额外的交联步骤，可提供具有优异循环性能的二次电池，以及一种用于凝胶聚合物电解质组合物的乙缩醛聚合物。提供了一种用于凝胶聚合物电解质组合物的乙烯基乙缩醛聚合物，其中乙烯基乙缩醛聚合物具有阳离子官能团，以及一种凝胶聚合物电解质组合物，该组合物由乙烯基乙缩醛聚合物和电解质溶液组成，其中乙烯基乙缩醛聚合物与电解质溶液的重量比为 0.5:99.5 至 9:91。
• HALO-ALLYLAMINE SSAO/VAP-1 INHIBITOR AND USE THEREOF
  申请人：Nanjing Transthera Biosciences Co., Ltd.

  公开号：EP3715341A1

  公开（公告）日：2020-09-30

  The present invention belongs to the pharmaceutical technical field, and specifically relates to a haloallylamine compound represented by formula I, a pharmaceutically acceptable salt, an ester or a stereoisomer thereof, R1, R2, R3, R4, R5, R6, L1, Cy1, R7 are defined as in the specification; the present invention also relates to pharmaceutical preparations and pharmaceutical compositions containing these compounds, and their use in preventing and/or treating the SSAO/VAP-1 protein-related or SSAO/VAP-1 protein-mediated disease.

  本发明属于医药技术领域，具体涉及一种由式I代表的卤代烯丙胺化合物、其药学上可接受的盐、酯或立体异构体，R1、R2、R3、R4、R5、R6、L1、Cy1、R7的定义如说明书；本发明还涉及含有这些化合物的药物制剂和药物组合物，以及它们在预防和/或治疗SSAO/VAP-1蛋白相关或SSAO/VAP-1蛋白介导的疾病中的用途。
• Tungsten processing slurry with catalyst
  申请人：Cabot Microelectronics Corporation

  公开号：US10066126B2

  公开（公告）日：2018-09-04

  Described are compositions (e.g., slurries) useful in methods for chemical-mechanical processing (e.g. polishing or planarizing) a surface of a substrate that contains tungsten, the slurries containing abrasive particles, metal cation catalyst, phosphorus-containing zwitterionic compound, and optional ingredients such as oxidizer; also described are methods and substrates used or processed on combination with the compositions.

  所述组合物（如浆料）适用于对含钨基材表面进行化学机械加工（如抛光或平面化）的方法，浆料含有研磨颗粒、金属阳离子催化剂、含磷齐聚物和氧化剂等任选成分；还描述了与组合物结合使用或加工的方法和基材。
• Dopamine D3 receptor antagonists
  申请人：Indivior UK Limited

  公开号：US10239870B2

  公开（公告）日：2019-03-26

  The disclosure is directed to novel dopamine D3 receptor antagonists, processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, including treating drug dependency and psychosis.

  本公开涉及新型多巴胺 D3 受体拮抗剂、其制备工艺、这些工艺中使用的中间体、含有它们的药物组合物及其在治疗中的用途，包括治疗药物依赖性和精神病。
• Dopamine D3 receptor antagonist compounds
  申请人：Indivior UK Limited

  公开号：US10654842B2

  公开（公告）日：2020-05-19

  The disclosure is directed to novel dopamine D3 receptor antagonists, processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, including treating drug dependency and psychosis.

  本公开涉及新型多巴胺 D3 受体拮抗剂、其制备工艺、这些工艺中使用的中间体、含有它们的药物组合物及其在治疗中的用途，包括治疗药物依赖性和精神病。